Navigation Links
FDA Issues Complete Response Letter for Ceftobiprole for Treatment of Complicated Skin Infections
Date:11/25/2008

RARITAN, N.J., Nov. 26 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ceftobiprole for the treatment of complicated skin and skin structure infections, including diabetic foot infections.

The FDA has indicated that they cannot approve the NDA for ceftobiprole at this time. They have asked J&JPRD to conduct additional audit work of clinical investigator sites and to address specific questions related to site monitoring.

J&JPRD and its co-development partner, Swiss-based Basilea Pharmaceutica Ltd., are reviewing the Complete Response letter and will continue to work with the FDA to resolve questions that are outlined in the Complete Response letter.

The NDA for ceftobiprole was submitted to the FDA in May 2007, and, in March 2008, J&JPRD received an Approvable Letter regarding the ceftobiprole filing. J&JPRD responded to the FDA's Approvable Letter in August 2008.

Ceftobiprole was approved earlier this year in Canada, and most recently it was approved in Switzerland. Last week, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended approval of ceftobiprole in the European Union for the treatment of complicated skin and soft tissue infections.

Ceftobiprole is a novel, broad-spectrum, anti-MRSA cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumonia and many clinically important Gram-negative bacteria, including Pseudomonas.

MRSA is a type of bacteria that is resistant to certain antibiotics. These antibiotics include methicillin and other more common antibiotics such as oxacil
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. College Mental Health Expert and Sister of Student Who Died By Suicide Available to Discuss College Mental Health Issues
2. PowerBar Issues Open Call for 2008-2009 PowerBar Team Elite(TM) Athlete Sponsorship Program
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
4. American Red Cross Issues Blood Supply Alert
5. OSHA Issues Draft Ergonomics Guidelines on Preventing Musculoskeletal Injuries in Shipyards
6. New Survey Finds Strong Public Interest in Prescription Drug Safety Issues
7. National Quality Forum Issues First Consensus Standards for the Treatment of Substance Use Conditions
8. Audio: New Survey Finds Strong Public Interest in Prescription Drug Safety Issues
9. Dallas-Area Transplant Meeting Puts Spotlight on Key Issues
10. Elder Care Author Doctor Marion Launches Second National Tour to Raise Awareness About Aging & Elder Care Issues in America
11. California State PTA Issues Statement Regarding Presidents Veto of SCHIP Legislation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... Quintessa Medical ... Kybella is a nonsurgical treatment designed specifically for the elimination of excess ... of the first locations in the state of Wisconsin to offer this innovative treatment. ...
(Date:7/30/2015)... ... 30, 2015 , ... The Tisch Cancer Institute at Icahn ... Tisch Cancer Institute (TCI) at the Icahn School of Medicine at Mount Sinai ... elite group of 69 cancer institutions nationwide that have earned this designation, which ...
(Date:7/30/2015)... ... July 30, 2015 , ... Author Dr. Raul Llanos seeks ... in his new self-help book, “ Consciously Healing our Webs of Health, Wellbeing, Success, ... message: “If we take responsibility for ourselves, we can create better realities.” His book ...
(Date:7/30/2015)... ... 30, 2015 , ... WellSpan Health in York, Pa., has ... claims for bariatric surgery that, despite complying with national and local coverage determinations, ... nurse auditor at WellSpan Health, tells Atlantic Information Services’ (AIS) Report on Medicare ...
(Date:7/30/2015)... ... ... weight, many people place a lot of focus on the different types of food that need ... another key component to successful weight gain is knowing when to eat so that ... Gainer gives three tips on when to eat to gain weight. , The first thing ...
Breaking Medicine News(10 mins):Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 3Health News:Hospital Details Fight for Bariatric Surgery Reimbursement in AIS Newsletter 2Health News:Hospital Details Fight for Bariatric Surgery Reimbursement in AIS Newsletter 3Health News:CB-1 Weight Gainer Gives Three Tips on When to Eat to Gain Weight 2Health News:CB-1 Weight Gainer Gives Three Tips on When to Eat to Gain Weight 3
... a part of National Health Service (NHS) that offers support to ... has decided// to cut hundreds of jobs as part of a ... going on about the issue. But unions fear that as many ... set up eight years ago as a new approach to take ...
... that periodontal disease is not a desirable condition in ... the first time researchers from Case Western Reserve University ... and Gynecology at MetroHealth Medical Center in Cleveland have ... ,Their report, titles, "Transmission of an Uncultivated Bergeyella Strain ...
... India the Reserve Bank of India (RBI) is not allowing ... and the State Bank of India (SBI) // facing difficulties ... , The Comprehensive Economic Cooperation Agreement (CECA) that was ... The Monetary Authority of Singapore (MAS), or central bank, ...
... people who suffer whiplash injuries can recover soon with ... Quebec, Canada.// The Whiplash Management strategy is a big ... initiative being better cost economy and earlier resumption of ... target, better practices in management of patient care that ...
... with inherited retinal degeneration have hope of vision since ... light sensitive that were not before.// ,Zhuo-Hua ... colleagues have engineered this technology using a harmless virus, ... "inner retinal neurons" in a strain of mice with ...
... of Kaiser Permanente, overweight or obesity during one’s middle ... in life. ,'The study was presented during ... San Diego. ,The researchers from the Kaiser ... 9,000 people for a period of 30 years. ...
Cached Medicine News:Health News:Strained Economic Agreement Between Singapore And India 2Health News:There is light at the end of the blind tunnel: prosthetic retinal cells offer hope! 2
(Date:7/30/2015)... 2015   HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing ... total revenue of $73.6 million for the quarter ... for the quarter ended June 30, 2014.  Currency ... or nine percentage points, during the three months ...
(Date:7/30/2015)... Maine, July 30, 2015  IDEXX Laboratories, Inc. (NASDAQ: ... quarter of 2015 of $413 million, an increase of ... the strengthening of the US dollar reduced reported revenue ... for the quarter was 11%, supported by strong growth ... per diluted share ("EPS") was $0.60 for the quarter, ...
(Date:7/29/2015)... FRANCISCO , July 29, 2015 Dignity ... Francis Orthopedic Institute, combining the services of the hospital,s ... in one centralized location, and expanding services to include ... the street from Saint Francis Memorial Hospital at 1199 ... Institute is a premier center aimed at providing a ...
Breaking Medicine Technology:HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 2HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 3HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 4HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 5HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 6HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 7HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 8HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 9HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 10HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 11HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 12HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 13HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 14IDEXX Laboratories Announces Second Quarter Results 2IDEXX Laboratories Announces Second Quarter Results 3IDEXX Laboratories Announces Second Quarter Results 4IDEXX Laboratories Announces Second Quarter Results 5IDEXX Laboratories Announces Second Quarter Results 6IDEXX Laboratories Announces Second Quarter Results 7IDEXX Laboratories Announces Second Quarter Results 8IDEXX Laboratories Announces Second Quarter Results 9IDEXX Laboratories Announces Second Quarter Results 10IDEXX Laboratories Announces Second Quarter Results 11IDEXX Laboratories Announces Second Quarter Results 12IDEXX Laboratories Announces Second Quarter Results 13IDEXX Laboratories Announces Second Quarter Results 14IDEXX Laboratories Announces Second Quarter Results 15IDEXX Laboratories Announces Second Quarter Results 16IDEXX Laboratories Announces Second Quarter Results 17IDEXX Laboratories Announces Second Quarter Results 18IDEXX Laboratories Announces Second Quarter Results 19IDEXX Laboratories Announces Second Quarter Results 20IDEXX Laboratories Announces Second Quarter Results 21IDEXX Laboratories Announces Second Quarter Results 22IDEXX Laboratories Announces Second Quarter Results 23
...   , First once-daily, fixed-dose ... (an irregular heartbeat) at risk of the devastating consequences ... single drug solution for the treatment of deep vein ... Xarelto is now approved in the UK for ...
... 19, 2011 BioMarin Pharmaceutical Inc. (Nasdaq: ... Products for Human Use (CHMP) of the European Medicines ... facility expansion in Novato, CA.  Final approval by the ... which would allow for products manufactured at the facility ...
Cached Medicine Technology:Bayer's Xarelto® (rivaroxaban) Becomes First Fixed Dose Once-Daily Anticoagulant Tablet Approved in the UK for Stroke Prevention in non-valvular Atrial Fibrillation; and the First Single Drug Regimen for Deep Vein Thrombosis 2Bayer's Xarelto® (rivaroxaban) Becomes First Fixed Dose Once-Daily Anticoagulant Tablet Approved in the UK for Stroke Prevention in non-valvular Atrial Fibrillation; and the First Single Drug Regimen for Deep Vein Thrombosis 3Bayer's Xarelto® (rivaroxaban) Becomes First Fixed Dose Once-Daily Anticoagulant Tablet Approved in the UK for Stroke Prevention in non-valvular Atrial Fibrillation; and the First Single Drug Regimen for Deep Vein Thrombosis 4Bayer's Xarelto® (rivaroxaban) Becomes First Fixed Dose Once-Daily Anticoagulant Tablet Approved in the UK for Stroke Prevention in non-valvular Atrial Fibrillation; and the First Single Drug Regimen for Deep Vein Thrombosis 5Bayer's Xarelto® (rivaroxaban) Becomes First Fixed Dose Once-Daily Anticoagulant Tablet Approved in the UK for Stroke Prevention in non-valvular Atrial Fibrillation; and the First Single Drug Regimen for Deep Vein Thrombosis 6BioMarin Receives Positive Opinion from European Regulatory Authorities for Expanded Biologics Manufacturing Facility 2BioMarin Receives Positive Opinion from European Regulatory Authorities for Expanded Biologics Manufacturing Facility 3